64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial

Wong, Keith; Sheehan-Dare, Gemma; Nguyen, Andrew; Ho, Bao; Liu, Victor; Brown, Lauren; Dear, Rachel; Chan, Lyn; Sharma, Shikha; Malaroda, Alessandra; Smith, Isabelle L; Lim, Elgene; Emmett, Louise

doi:10.3390/ph15070772

Cited by 10 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical trial was designed to assess the safety and potential of [ 64 Cu]Cu(Sar-BBN) PET imaging in restaging estrogen receptor-positive (ER+), progesterone receptor positive (PR+), and human epidermal growth-factor-2-negative (HER2−) breast cancer patients. In this study, patients with metastatic ER+/PR+/HER2– breast cancer underwent PET/CT with [ 64 Cu]Cu(Sar-BBN) . The results were extremely encouraging, and it was possible to conclude that the agent appears safe and may have a diagnostic and theranostic utility in subtypes of metastatic ER+/PR+/HER2– breast cancer patients, especially the lobular subtype, with excellent tumor visualization 24 h pi (Figure ).…”

Section: Theranostic Opportunities With “Matched” Pair Radionuclidesmentioning

confidence: 91%

“…This fractionated treatment resulted in a 93% reduction in tumor volume on day 19 compared to control mice with no noticeable signs of toxicity. 159 The results were extremely encouraging, and it was possible to conclude that the agent appears safe and may have a diagnostic and theranostic utility in subtypes of metastatic ER+/PR+/HER2− breast cancer patients, especially the lobular subtype, with excellent tumor visualization 24 h pi (Figure 17).…”

Section: Diagnostic Imaging and Therapy With [ 64/67 Cu]cusar-bombesinmentioning

confidence: 94%

See 1 more Smart Citation

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides

Morgan,

Rudd,

Noor

et al. 2023

Chem. Rev.

View full text Add to dashboard Cite

Molecular changes in malignant tissue can lead to an increase in the expression levels of various proteins or receptors that can be used to target the disease. In oncology, diagnostic imaging and radiotherapy of tumors is possible by attaching an appropriate radionuclide to molecules that selectively bind to these target proteins. The term “theranostics” describes the use of a diagnostic tool to predict the efficacy of a therapeutic option. Molecules radiolabeled with γ-emitting or β+-emitting radionuclides can be used for diagnostic imaging using single photon emission computed tomography or positron emission tomography. Radionuclide therapy of disease sites is possible with either α-, β-, or Auger-emitting radionuclides that induce irreversible damage to DNA. This Focus Review centers on the chemistry of theranostic approaches using metal radionuclides for imaging and therapy. The use of tracers that contain β+-emitting gallium-68 and β-emitting lutetium-177 will be discussed in the context of agents in clinical use for the diagnostic imaging and therapy of neuroendocrine tumors and prostate cancer. A particular emphasis is then placed on the chemistry involved in the development of theranostic approaches that use copper-64 for imaging and copper-67 for therapy with functionalized sarcophagine cage amine ligands. Targeted therapy with radionuclides that emit α particles has potential to be of particular use in late-stage disease where there are limited options, and the role of actinium-225 and lead-212 in this area is also discussed. Finally, we highlight the challenges that impede further adoption of radiotheranostic concepts while highlighting exciting opportunities and prospects.

show abstract

Section: Theranostic Opportunities With “Matched” Pair Radionuclidesmentioning

confidence: 91%

Section: Diagnostic Imaging and Therapy With [ 64/67 Cu]cusar-bombesinmentioning

confidence: 94%

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides

Morgan,

Rudd,

Noor

et al. 2023

Chem. Rev.

View full text Add to dashboard Cite

show abstract

“…A recent study included seven patients with metastatic hormone-positive/HER2 negative BC that performed both [ 18 F]FDG and [ 64 Cu]SAR-BBN PET/CT for re-staging purposes. Two of the seven patients had classical ILC, and images showed greater uptake and tumor volume on [ 64 Cu]SAR-BBN PET/CT compared to FDG PET/CT (SUVmax 20 vs. 11 and 20 vs. <3) [88]. GRPR-positive BC with GRPR radioligands is a promising target for radioligand therapy as well, especially in ER-positive BC patients.…”

Section: Pet With Other Radiopharmaceuticalsmentioning

confidence: 92%

FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma

et al. 2023

View full text Add to dashboard Cite

Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is extensively used in oncology and BC patient evaluation. Its role in ILCs is considered suboptimal due to its low FDG avidity. Therefore, ILCs could benefit from molecular imaging with non-FDG tracers that target other specific pathways, contributing to precision medicine. This narrative review aims to summarize the current literature on the use of FDG-PET/CT in ILC and to discuss future opportunities given by the development of innovative non-FDG radiotracers.

show abstract

“…Future directions include the use on other radiopharmaceuticals targeting estrogen and Her-2 receptor status, angiogenesis, or gastrin-releasing peptide receptor expression [126].…”

Section: Breast Cancermentioning

confidence: 99%

International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology

Veit-Haibach,

Ahlström,

Boellaard

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Preamble The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. The merged International Society for Magnetic Resonance in Medicine (ISMRM) is an international, nonprofit, scientific association whose purpose is to promote communication, research, development, and applications in the field of magnetic resonance in medicine and biology and other related topics and to develop and provide channels and facilities for continuing education in the field.The ISMRM was founded in 1994 through the merger of the Society of Magnetic Resonance in Medicine and the Society of Magnetic Resonance Imaging. SNMMI, ISMRM, and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine and/or magnetic resonance imaging. The SNMMI, ISMRM, and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and/or magnetic resonance imaging and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice guideline, representing a policy statement by the SNMMI/EANM/ISMRM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI, ISMRM, and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging and magnetic resonance imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized. These guidelines are an educational tool designed to assist practitioners in providing appropriate care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI, the ISMRM, and the EANM caution against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, there is no implication that an approach differing from the guidelines, standing alone, is below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines. The practice of medicine includes both the art and the science of the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these guidelines will not ensure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.

show abstract

64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial

Cited by 10 publications

References 26 publications

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides

FDG and Non-FDG Radiopharmaceuticals for PET Imaging in Invasive Lobular Breast Carcinoma

International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology

Contact Info

Product

Resources

About